Category	Price
Until 10/31/13	$100
Beginning 11/1/13	$120

(When registering you must provide name of organization you are representing)

Click here to register and for further registration information.

Pre-registration discount ends October 31, 2013.

Pre-registration closes November 15, 2013.
On site registration opens December 10, 2013.

The Alamo Breast Cancer Foundation runs a grassroots advocacy program to eradicate the presence of breast cancer in our society.

Every year, Alamo Breast Cancer Foundation sponsors special mentoring sessions for patient advocates at SABCS. These usually take place 5 PM – 8 PM on Wednesday, Thursday & Friday during the symposium.

Leading experts in the field of breast cancer provide commentary on symposium presentations and responding to advocates’ questions about the relevance of this scientific data.

Every year the Alamo Breast Cancer Foundation provides scholarships for eligible breast cancer advocates to attend the annual San Antonio Breast Cancer Symposium, and take part in Mentor Sessions.

Website
Information regarding the 2013 ABCF Advocate Program can be found at www.alamobreastcancer.org.  This page also includes a link to an on line application.

E-Mail
sandisues@sbcglobal.net for information and an application.

All applications for financial assistance must be submitted by 10PM CST by September 1, 2013.

The 15th Annual Advocate Program is sponsored by Alamo Breast Cancer Foundation (ABCF), a non-profit 501[c]3 organization. This San Antonio-based grassroots advocacy, educational, and support organization was established for women and men with breast cancer and for those concerned about breast cancer issues. ABCF is active locally and nationally (as members of the National Breast Cancer Coalition) in their goal to eradicate breast cancer in our lifetime.

The 1st Annual Advocate Program was held in 1998, in conjunction with the 21st Annual San Antonio Breast Cancer Symposium, as an educational program specially designed to address the needs of
patient advocates and those who support them. The program for 2012 will include Orientation, Dinner, Mentors Program, and Breast Cancer Update for the grant recipients. 40-50 travel grants are expected to be available for 2012, pending receipt of sufficient grant funds.

The administration of this program is handled entirely by Alamo Breast Cancer Foundation. Their 2012 proposal will be mailed to a select list in June, and we hope you will support their program in addition to the 35th Annual San Antonio Breast Cancer Symposium.

Contact Information:
Sandi Stanford
Alamo Breast Cancer Foundation
PO Box 780067
San Antonio, TX 78278
Email: sandisues@sbcglobal.net
Website Address: www.alamobreastcancer.org

Year	Funding Sources	# Travel Grants Applications	# Travel Grants Awarded	Total # Advocate Registration to SABCS
1998	Glaxo Wellcome Eli Lilly Zeneca	14	14	82
1999	Bristol-Myers Genentech Wyeth-Ayerst	42	30	104
2000	Aventis Genentech AstraZeneca Glaxo Wellcome Pharmacia Oncology	62	50	123
2001	AstraZeneca Aventis Bristol-Meyers Squibb Chroma Vision Eli Lilly Genentech GlaxoSmithKline Pharmacia	52	36	118
2002	AstraZeneca Aventis Bristol-Myers Squibb ChromaVision DakoCytomation Eli Lilly Genentech GlaxoSmithKline Pharmacia	40	28	119
2003	AstraZeneca Pharmaceuticals Bristol Myers Squibb Chromavision DakoCytomation Eli Lilly & Co Genentech Genomic Health GlaxoSmithKline Pfizer	52	37	168
2004	AstraZeneca Pharmaceuticals DakoCytomatic, Inc. Genentech, Inc. Genomic Health, Inc. GlaxoSmithKline Introgen Therapeutics, Inc. Sanofi-Aventis	52	37	168
2005	AstraZeneca Pharmaceuticals Cytyc Eli Lilly & Company Genentech Genomic Health GlaxoSmithKline Introgen Therapeutics Sanofi-Aventis	49	32	201
2006	Avon Foundation NBCC Fund--Best Practices Award AstraZeneca Genentech Genomic Health Eli Lilly Sanofi-Aventis	109	43	199
2007	Abraxis Oncology AstraZeneca Avon Foundation Genentech GlaxoSmithKline Novartis Roche Introgen Therapeutics Sanofi-Aventis Dr. Sharon Wilks	109	42	233
2008	Abraxane-AZ AstraZeneca Avon Foundation Cytori Genentech BioOncology Genomic Health, Inc. GlaxoSmithKline Her2 Support Novartis Roche Sanofi-Aventis Dr. Sharon Wilks	34	32	225
2009	Abraxis BioOncology AstraZeneca Avon Foundation for Women Cytori Therapeutics, Inc Eli Lilly & Co Genentech Genomic Health, Inc GlaxoSmithKline Her2 Support Group Organization National Breast Cancer Coalition Novartis Pharmaceuticals Corp Sanofi-Aventis Dr. Sharon Wilks, MD, FACP Dr. Peter Ravdin, MD, PhD	82	36	235
2010	AACR Abraxis BioOncology Amgen AstraZeneca Avon Foundation for Women Eisai, Inc. Eli Lilly & Co. Genentech GlaxoSmithKline Novartis Pharmaceuticals Corporation Dr. Peter Ravdin, MD, PhD Sanofi-Aventis Dr Sharon Wilks, MD, FACP	107	32	297
2011	AACR Amgen Avon Foundation for Women Boehringer Ingelheim Genentech Genomic Health, Inc. GlaxoSmithKline Julie Ann Carpenter Memorial Fund Novartis Pharmaceuticals Corp Peter Ravdin, MD, PhD Sharon Wilks, MD, FACP Syndax	119	41	298
2012	AACR Amgen Avon Foundation for Women Celgene Corporation Genentech Genomic Health, Inc GlaxoSmithKline Julie Ann Carpenter Memorial Fund Nektar Novartis Pharmaceuticals Corp Peter Ravdin, MD, PhD	68	31	144